| 来源类型 | Working Paper |
| 规范类型 | 论文 |
| India’s paradox: The largest drug exporter and the most isolationist drug industry | |
| Roger Bate; Amir Attaran; Dinesh Thakur | |
| 发表日期 | 2013-12-02 |
| 出版年 | 2013 |
| 语种 | 英语 |
| 摘要 | The reach of the Indian pharmaceutical industry is enormous. India supplies a large and increasing amount of the generic drugs sold globally, and the country is home to over 150 drug manufacturing facilities approved by the US Food and Drug Administration1—including many run by multinational players. The value of pharmaceutical exports from India to the United States rose nearly 32 percent in 2012, to $4.2 billion.2 India supplies nearly 40 percent of generic drugs and over-the-counter products as well as 10 percent of finished dosages used in the US.3 Some of these products are very substantial: Ranbaxy, one of India’s largest pharmaceutical companies, won the right to make the only generic version of Lipitor for sale to Americans when it was the world’s best selling drug with peak annual sales of over $12 billion.4 India is one of the largest suppliers for the Internet market in western countries and is the dominant provider in most emerging markets, too. India’s paradox: The largest drug exporter and the most isolationist drug industry by American Enterprise Institute |
| 主题 | Health Care |
| 标签 | Counterfeit pharmaceuticals ; exports ; FDA ; imports ; Pharmaceuticals ; US-India relations |
| URL | https://www.aei.org/research-products/working-paper/indias-paradox-the-largest-drug-exporter-and-the-most-isolationist-drug-industry/ |
| 来源智库 | American Enterprise Institute (United States) |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/207292 |
| 推荐引用方式 GB/T 7714 | Roger Bate,Amir Attaran,Dinesh Thakur. India’s paradox: The largest drug exporter and the most isolationist drug industry. 2013. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
